Please login to the form below

Not currently logged in
Email:
Password:

Valeant appoints company group chairman

Ari Kellen joins from McKinsey & Company

Fast-growing Canadian pharma company Valeant Pharmaceuticals has appointed Dr Ari Kellen as executive VP and company group chairman.

Dr Kellen joins from McKinsey & Company where he was a senior partner at the consultancy firm's mid-Atlantic office.

He spent 22 years at McKinsey leading a number of a studies for healthcare companies, including corporate strategies for boards and top management teams, business unit strategies for medical device, pharma and biotech, and health care services clients, and regional and country growth strategies.

J Michael Pearson, chairman and CEO of Valeant, said: "Ari's broad experience in developing comprehensive growth strategies for healthcare companies will be invaluable to us as we continue to expand our successful growth trends.

“After having worked with Ari for many years, I know that not only will he fit in well with the rest of the team, but he will be a strong advocate for the long-term shareholder focused culture at Valeant."

28th November 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....